Success Metrics

Clinical Success Rate
86.7%

Based on 13 completed trials

Completion Rate
87%(13/15)
Active Trials
3(8%)
Results Posted
31%(4 trials)
Terminated
2(5%)

Phase Distribution

Ph phase_1
2
5%
Ph phase_2
2
5%
Ph phase_3
3
8%
Ph phase_4
8
20%
Ph not_applicable
19
48%

Phase Distribution

2

Early Stage

2

Mid Stage

11

Late Stage

Phase Distribution34 total trials
Phase 1Safety & dosage
2(5.9%)
Phase 2Efficacy & side effects
2(5.9%)
Phase 3Large-scale testing
3(8.8%)
Phase 4Post-market surveillance
8(23.5%)
N/ANon-phased studies
19(55.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.7%

13 of 15 finished

Non-Completion Rate

13.3%

2 ended early

Currently Active

3

trials recruiting

Total Trials

40

all time

Status Distribution
Active(4)
Completed(13)
Terminated(2)
Other(21)

Detailed Status

unknown21
Completed13
Recruiting2
Terminated2
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
40
Active
3
Success Rate
86.7%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (5.9%)
Phase 22 (5.9%)
Phase 33 (8.8%)
Phase 48 (23.5%)
N/A19 (55.9%)

Trials by Status

recruiting25%
terminated25%
not_yet_recruiting13%
active_not_recruiting13%
unknown2153%
completed1333%

Recent Activity

Clinical Trials (40)

Showing 20 of 40 trialsScroll for more
NCT02435953Phase 3

TACE+RFA Versus TACE Alone for Intermediate-stage Hepatocellular Carcinoma

Completed
NCT03041805

Caprini Score in Venous Surgery: a Prospective Cohort Study

Recruiting
NCT07252180Not Applicable

Comparing Two Different Methods of Ablation of Inlet Patches (APC vs RFA)

Active Not Recruiting
NCT04129411Not Applicable

Treatment of Papillary Thyroid Carcinoma With Radiofrequency Ablation

Completed
NCT05519319Not Applicable

Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma

Recruiting
NCT05277675Not Applicable

Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)

Unknown
NCT03720210Not Applicable

Radiofrequency Ablation for Amiodarone-induced Thyrotoxicosis

Terminated
NCT04864379Phase 1

Clinical Study of a Personalized Neoantigen Cancer Vaccine Combined With Anti-PD-1 and RFA in Patients With Solid Tumors

Unknown
NCT03375281Not Applicable

Radiofrequency Ablation Using Octopus Electrodes for Small Hepatocellular Carcinoma With No-touch Technique

Completed
NCT03722134Not Applicable

Mechanochemical Ablation vs Thermal Ablation

Completed
NCT02917538Not Applicable

A Randomized Trial of Contact Force in Atrial Flutter Ablation

Completed
NCT04530097Not Applicable

Radiofrequency Ablation Combined With Melatonin in the Treatment of Stage IA NSCLC

Unknown
NCT01853618Phase 1

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

Completed
NCT03790059Not Applicable

Radiofrequency Ablation Combined With Recombinant Human Adenovirus Type 5 in the Treatment of Hepatocellular Carcinoma.

Unknown
NCT01570166Not Applicable

Percutaneous Radiofrequency Ablation Versus Repeat Hepatectomy for Recurrent Hepatocellular Carcinoma

Unknown
NCT01126645Phase 2

Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer

Completed
NCT03395379

Air Dissection in Percutaneous Radiofrequency Ablation of T1a Renal Cell Carcinoma

Completed
NCT02614885

Feasibility Study of Cavitary Radiofrequency Ablation in Excised Mastectomy Breast Tissue

Completed
NCT02138578Not Applicable

Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma

Terminated
NCT03097848Not Applicable

Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma

Unknown

Drug Details

Intervention Type
PROCEDURE
Total Trials
40